GlassScriptPhysician profile
Jeanne C Morrow
NPI 1861434078
$3,329.03
in general payments reported to CMS, 2019-2025
22 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $347 · 2021: $98.05 · 2022: $101 · 2023: $501 · 2024: $549 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $467.27 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $440.64 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $366.86 | 2019-2021 | |
| Axsome Therapeutics, INC. | $280.70 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $275.32 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $274.04 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $234.67 | 2019-2020 | |
| Allergan, INC. | $153.72 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.34 | 2019-2023 | Trintellix |
| Abbvie INC. | $133.50 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $131.70 | 2019-2023 | Ingrezza |
| Vanda Pharmaceuticals INC. | $76.27 | 2023-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $64.01 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $53.25 | 2024-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $42.41 | 2022-2023 | Qelbree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $40.00 | 2019 | |
| Adlon Therapeutics L.P. | $32.60 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $28.72 | 2019 | |
| Tris Pharma INC | $25.12 | 2019 | |
| Alkermes, INC. | $20.71 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.44 | 2025 | Jornay Pm |
| Shire North American Group INC | $16.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanne Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.